News & Announcements

Weil Advised Sanofi in its $11.6B Acquisition of Bioverativ

Weil advised Sanofi in its $11.6 billion acquisition of Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, under which Sanofi acquired all of the outstanding shares of Bioverativ Inc. for $105 per share in cash. The transaction closed March 8, 2018.

The Weil team that advised Sanofi was led by Corporate Chairman and Mergers & Acquisitions partner Michael Aiello and included Mergers & Acquisitions partner Sachin Kohli; Mergers & Acquisitions associates Katie Simmonds, Michelle Sargent, Sarah Fries, Elisabeth McMorris and Sam Hulsey; Technology & IP Transactions partner Jeffrey Osterman; Tax partner Chayim Neubort; Executive Compensation & Benefits Head Paul Wessel; Antitrust partner John Scribner; White Collar Defense, Regulatory and Investigations partner Holly Loiseau; Patent Litigation partner Elizabeth Weiswasser; Environmental counsel John O’Loughlin; Antitrust counsel Michael Naughton; Technology & IP Transactions associates Jennifer Yoon, Daniel Cohl and Rami Sherman; Tax associate Gary Silber; Executive Compensation & Benefits associates Jennifer Haydel Britz and John Kleinjan; Antitrust associate Leslie Roter; and Patent Litigation associates Kathryn Kantha and Priyata Patel.